Why Dyne Therapeutics Stock Was Blasting Higher Today

Dyne Therapeutics (NASDAQ: DYN) was hardly having a bad case of the Mondays. Shares of the clinical-stage biotech were racing more than 9% higher in mid-session action, as the company delivered rather encouraging news about one of its investigational drugs. Before market open, Dyne announced that its zeleciment rostudirsen -- a treatment targeting the genetic disorder Duchenne muscular dystrophy (DMD) -- had achieved its primary endpoint in a phase 1/2 clinical trial involving 86 patients. It also met its secondary endpoints. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool